These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 24374965)

  • 1. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
    Antrobus RD; Coughlan L; Berthoud TK; Dicks MD; Hill AV; Lambe T; Gilbert SC
    Mol Ther; 2014 Mar; 22(3):668-674. PubMed ID: 24374965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
    Boyd AC; Ruiz-Hernandez R; Peroval MY; Carson C; Balkissoon D; Staines K; Turner AV; Hill AV; Gilbert SC; Butter C
    Vaccine; 2013 Jan; 31(4):670-5. PubMed ID: 23200938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.
    Vitelli A; Quirion MR; Lo CY; Misplon JA; Grabowska AK; Pierantoni A; Ammendola V; Price GE; Soboleski MR; Cortese R; Colloca S; Nicosia A; Epstein SL
    PLoS One; 2013; 8(3):e55435. PubMed ID: 23536756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge.
    McMahon M; Asthagiri Arunkumar G; Liu WC; Stadlbauer D; Albrecht RA; Pavot V; Aramouni M; Lambe T; Gilbert SC; Krammer F
    Front Immunol; 2019; 10():2005. PubMed ID: 31497029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.
    Asthagiri Arunkumar G; McMahon M; Pavot V; Aramouni M; Ioannou A; Lambe T; Gilbert S; Krammer F
    Vaccine; 2019 Sep; 37(37):5567-5577. PubMed ID: 31399277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
    Berthoud TK; Hamill M; Lillie PJ; Hwenda L; Collins KA; Ewer KJ; Milicic A; Poyntz HC; Lambe T; Fletcher HA; Hill AV; Gilbert SC
    Clin Infect Dis; 2011 Jan; 52(1):1-7. PubMed ID: 21148512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of CD8
    Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A
    Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.
    Mullin J; Ahmed MS; Sharma R; Upile N; Beer H; Achar P; Puksuriwong S; Ferrara F; Temperton N; McNamara P; Lambe T; Gilbert SC; Zhang Q
    Vaccine; 2016 Mar; 34(14):1688-95. PubMed ID: 26902548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
    Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais ME; Duncan CJ; Sheehy SH; Havelock T; Faust SN; Williams RL; Gilbert A; Oxford J; Dong T; Hill AV; Gilbert SC
    Clin Infect Dis; 2012 Jul; 55(1):19-25. PubMed ID: 22441650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT;
    Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.
    Roy S; Kobinger GP; Lin J; Figueredo J; Calcedo R; Kobasa D; Wilson JM
    Vaccine; 2007 Sep; 25(39-40):6845-51. PubMed ID: 17728024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.
    Altenburg AF; Magnusson SE; Bosman F; Stertman L; de Vries RD; Rimmelzwaan GF
    Clin Exp Immunol; 2017 Oct; 190(1):19-28. PubMed ID: 28665497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
    Huang B; Wang W; Li R; Wang X; Jiang T; Qi X; Gao Y; Tan W; Ruan L
    Virol J; 2012 Dec; 9():322. PubMed ID: 23272943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults.
    Coughlan L; Sridhar S; Payne R; Edmans M; Milicic A; Venkatraman N; Lugonja B; Clifton L; Qi C; Folegatti PM; Lawrie AM; Roberts R; de Graaf H; Sukhtankar P; Faust SN; Lewis DJM; Lambe T; Hill A; Gilbert SC
    EBioMedicine; 2018 Mar; 29():146-154. PubMed ID: 29519670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
    Pandey A; Singh N; Vemula SV; Couëtil L; Katz JM; Donis R; Sambhara S; Mittal SK
    PLoS One; 2012; 7(3):e33428. PubMed ID: 22432020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.
    Zhou D; Wu TL; Emmer KL; Kurupati R; Tuyishime S; Li Y; Giles-Davis W; Zhou X; Xiang Z; Liu Q; Ratcliffe SJ; Ertl HC
    Mol Ther; 2013 Mar; 21(3):696-706. PubMed ID: 23229092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.
    Magini D; Giovani C; Mangiavacchi S; Maccari S; Cecchi R; Ulmer JB; De Gregorio E; Geall AJ; Brazzoli M; Bertholet S
    PLoS One; 2016; 11(8):e0161193. PubMed ID: 27525409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.
    Johnson PV; Blair BM; Zeller S; Kotton CN; Hohmann EL
    Microbiol Immunol; 2011 May; 55(5):304-17. PubMed ID: 21338384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.